SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
BrainCells Gets $8M In First Part Of Committed $17.7M Series A
News | 07. 15. 2005
BrainCells
BrainCells Inc., a neuroscience-focused drug discovery and development company targeting therapies for depression, related neuropsychiatric disorders and other central nervous system diseases, has closed on commitments of $17.7 million for its Series A round.
